Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Noninterventional Epigenomic Mapping of CD34+ Cells From Healthy Participants and Patients with Myelofibrosis (MF) and Polycythemia Vera (PV)

Hematologic

Hematologic
N/A
Savona, Michael
VICCHEM18100

Understanding Function and Outcomes in Patients Receiving Immune Checkpoint Inhibitors

Miscellaneous

Miscellaneous
N/A
Johnson, Douglas
VICCMD18106

Testing Treatment with Ipilimumab and Nivolumab Compared to Treatment with Ipilimumab Alone in Advanced Melanoma

Melanoma

This phase II trial studies how well ipilimumab with or without nivolumab work in treating patients with melanoma that is stage IV or stage III and cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Melanoma
II
Johnson, Douglas
NCT03033576
ECOGMELS1616

A Phase 1 / 2 Study to Evaluate SNDX- 6352 in Subjects With Active cGVHD

Multiple Cancer Types

This is a Phase 1 / 2, Open-label, Dose Escalation study to investigate SNDX-6352 in subjects with active cGVHD.
Hematologic, Phase I
I
Jagasia, Madan
NCT03604692
VICCBMTP18109


Nashville Biosciences Blood Sample Collection Study

Multiple Cancer Types

Colon, Liver, Lung, Non Small Cell, Ovarian, Pancreatic, Rectal
N/A
Bernard, Gordon
VICCMD18123

Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Multiple Cancer Types

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).
Lung, Non Small Cell
II
Horn, Leora
NCT03539536
VICCTHO18125

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and / or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Breast

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and / or metastatic breast cancer subjects previously treated with trastuzumab and taxane.
Breast
III
Rexer, Brent
NCT03529110
VICCBRE18126

Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian / Tubal Tissue to Determine Presence of Malignancy

Gynecologic

Prospective, multi-center, non-randomized study to assess the ability of the Cytuity device to collect cell samples from the fallopian tube that can be evaluated for the presence or absence of malignancy.
Gynecologic
N/A
Anderson, Ted
NCT03593681
VICCGYN18131

Provision of Free Varenicline (Chantix) within the Context of a Dedicated Outpatient Tobacco Treatment Clinic (TTC) for Cancer Patients

Lung

Lung
N/A
Tindle, Hilary
VICCTHO18132

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: